Zhang et al. discovered through their case study that ertanecept was effective in reducing the levels of TNF-α (p = 0.03), IL-6 (p = 0.007), and IL-10 (p = 0.01) in eight patients undergoing CAR-T therapy and with symptoms associated with CRS [37]. Here, IL10 is linked to congenital rubella syndrome.